Kyverna Therapeutics Inc. (KYTX) Statistics & Valuation Metrics - Stocknear

Kyverna Therapeutics Inc.

NASDAQ: KYTX · Real-Time Price · USD
3.94
0.31 (8.54%)
At close: Sep 05, 2025, 3:59 PM
3.92
-0.53%
After-hours: Sep 05, 2025, 05:37 PM EDT

Kyverna Therapeutics Statistics

Share Statistics

Kyverna Therapeutics has 43.25M shares outstanding. The number of shares has increased by 0.17% in one year.

43.25M
0.17%
0.01%
59.67%
22.47M
9,808
2.38%

Short Selling Information

The latest short interest is 1.58M, so 3.65% of the outstanding shares have been sold short.

1.58M
3.65%
6.35%
5.61

Valuation Ratios

The PE ratio is -1.12 and the forward PE ratio is -1.01. Kyverna Therapeutics's PEG ratio is 0.

-1.12
-1.01
0
13.6
0.54
-1.23
0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Kyverna Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.03.

8.61
8.61
0.03
-0.07
-0.07
-1004.25

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.14M
112
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by -46.32% in the last 52 weeks. The beta is 3.1, so Kyverna Therapeutics's price volatility has been higher than the market average.

3.1
-46.32%
3.58
3.19
59.44
411,698

Income Statement

n/a
-2.13M
-142.6M
-127.48M
-125.2M
-127.33M
-3.33
Full Income Statement

Balance Sheet

The company has 96.62M in cash and 8.24M in debt, giving a net cash position of 88.38M.

96.62M
8.24M
88.38M
-263.52M
226.51M
174.54M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -114.25M and capital expenditures -2.21M, giving a free cash flow of -116.45M.

-114.25M
-2.21M
-116.45M
-3.04
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

KYTX does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for KYTX is $16.5, which is 318.8% higher than the current price. The consensus rating is "Buy".

$16.5
318.8%
Buy
5
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

-1.34
2